Sign in to edit your profile (add interests, mentoring, photo, etc.)

    John Metcalfe, MD, PhD, MPH

    TitleAssistant Professor
    SchoolUCSF School of Medicine
    DepartmentMedicine
    Address1001 Potrero Ave, SFGH 5
    San Francisco CA 94143
    Phone415-596-9348

       Biography 
       Education and Training
      Institution Degree School or Department Year
      University of California, San FranciscoResidency Internal Medicine

       Overview 
       Overview
      I am an Assistant Professor in the Division of Pulmonary and Critical Care Medicine and the Curry International Tuberculosis Center, both at the University of California, San Francisco. My research interests focus on the diagnosis, management, and transmission of tuberculosis and other pulmonary infectious diseases, domestically and in high HIV-burden settings. I have specialized training in clinical research methods, statistical prediction, repeated measures, and causal inference through a Ph.D. obtained within the Division of Epidemiology at UC Berkeley.

      Domestic collaborations with the Tuberculosis Control Branch of the California Department of Public Health have resulted in publications on state-wide epidemiologic trends in TB/HIV co-morbidity and its changing relationship among immigrants, as well as the molecular epidemiology of drug-resistant TB. Application of specialized statistical techniques to analyze the clinical utility of interferon-gamma release assays (IGRAs) has led to two first-author publications in the American Journal of Respiratory and Critical Care Medicine. Internationally, I have worked as a technical consultant to the Pan American Health Organization (PAHO), Program for Appropriate Technology in Health (PATH), and USAID in national TB program evaluation, programmatic guidelines, and multidrug resistant tuberculosis operational plan development, including in Zimbabwe. Since 2011, I have enrolled over 400 individuals at risk for drug-resistant TB (K23 AI094251, Transmission and Pathogenesis of MDR-TB (Trap MDR-TB)) in Harare, Zimbabwe. Here, we produced the first population-based estimate of MDR-TB since 1995, improved time to diagnosis for MDR-TB from over one year to nine days, and validated low-cost diagnostic platforms for local use. Within this cohort, an unusual number of HIV-infected individuals, especially adolescents, were noted to have chronic respiratory symptoms in absence of TB or other apparent etiology. In collaboration with world-class UCSF researchers, we now aim to characterize the clinical manifestations, immune ontogeny, and microbiome (the ecological community of microorganisms) of this unique patient group. Finally, through a recently funded NIH/Fogarty award (D43 TW009539), we have begun to strengthen the capacity of the UZ College of Health Sciences (UZCHS) to replenish its ranks of high-quality junior faculty and to conduct high quality, innovative, and locally relevant TB and HIV/AIDS research. I currently hold an appointment as Lecturer within the University of Zimbabwe, and act as consultant to the NIH Division of AIDS UZ/UCSF Clinical Trials Unit.


       ORNG Applications 
       Websites
       NIH Grants Awarded
       Global Health
       More Info

       Bibliographic 
       Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Metcalfe JZ, Mason P, Mungofa S, Sandy C, Hopewell PC. Empiric tuberculosis treatment in retreatment patients in high HIV/tuberculosis-burden settings. Lancet Infect Dis. 2014 Sep; 14(9):794-5.
        View in: PubMed
      2. Davis JL, Kawamura LM, Chaisson LH, Grinsdale J, Benhammou J, Ho C, Babst A, Banouvong H, Metcalfe JZ, Pandori M, Hopewell PC, Cattamanchi A. Impact of GeneXpert MTB/RIF® on Patients and Tuberculosis Programs in a Low-Burden Setting: A Hypothetical Trial. Am J Respir Crit Care Med. 2014 May 28.
        View in: PubMed
      3. Metcalfe JZ, Makumbirofa S, Makamure B, Sandy C, Bara W, Mungofa S, Hopewell PC, Mason P. Drug-resistant tuberculosis in high-risk groups, zimbabwe. Emerg Infect Dis. 2014 Jan; 20(1):135-7.
        View in: PubMed
      4. Pai M, Denkinger CM, Kik SV, Rangaka MX, Zwerling A, Oxlade O, Metcalfe JZ, Cattamanchi A, Dowdy DW, Dheda K, Banaei N. Gamma Interferon Release Assays for Detection of Mycobacterium tuberculosis Infection. Clin Microbiol Rev. 2014 Jan; 27(1):3-20.
        View in: PubMed
      5. Millman AJ, Dowdy DW, Miller CR, Brownell R, Metcalfe JZ, Cattamanchi A, Davis JL. Rapid Molecular Testing for TB to Guide Respiratory Isolation in the U.S.: A Cost-Benefit Analysis. PLoS One. 2013; 8(11):e79669.
        View in: PubMed
      6. Prach LM, Pascopella L, Barry PM, Flood J, Porco TC, Hopewell PC, Metcalfe JZ. Rifampin monoresistant tuberculosis and HIV comorbidity in California, 1993-2008: a retrospective cohort study. AIDS. 2013 Oct 23; 27(16):2615-22.
        View in: PubMed
      7. Cattamanchi A, Walter ND, Metcalfe JZ, Davis JL. A transcriptional signature for active TB: have we found the needle in the haystack? PLoS Med. 2013 Oct; 10(10):e1001539.
        View in: PubMed
      8. Gopal M, Padayatchi N, Metcalfe JZ, O'Donnell MR. Systematic review of clofazimine for the treatment of drug-resistant tuberculosis. Int J Tuberc Lung Dis. 2013 Aug; 17(8):1001-7.
        View in: PubMed
      9. Metcalfe JZ, Porco TC, Westenhouse J, Damesyn M, Facer M, Hill J, Xia Q, Watt JP, Hopewell PC, Flood J. Tuberculosis and HIV co-infection, California, USA, 1993–2008. Emerg Infect Dis. 2013 Mar; 19(3):400-6.
        View in: PubMed
      10. Makamure B, Mhaka J, Makumbirofa S, Mutetwa R, Mupfumi L, Mason P, Metcalfe JZ. Microscopic-observation drug-susceptibility assay for the diagnosis of drug-resistant tuberculosis in Harare, Zimbabwe. PLoS One. 2013; 8(2):e55872.
        View in: PubMed
      11. Metcalfe JZ, Cattamanchi A, McCulloch CE, Lew JD, Ha NP, Graviss EA. Test variability of the QuantiFERON-TB gold in-tube assay in clinical practice. Am J Respir Crit Care Med. 2013 Jan 15; 187(2):206-11.
        View in: PubMed
      12. Dantes R, Metcalfe J, Kim E, Kato-Maeda M, Hopewell PC, Kawamura M, Nahid P, Cattamanchi A. Impact of isoniazid resistance-conferring mutations on the clinical presentation of isoniazid monoresistant tuberculosis. PLoS One. 2012; 7(5):e37956.
        View in: PubMed
      13. Metcalfe JZ, Porco TC, Westenhouse J, Damesyn M, Facer M, Hill J, Xia Q, Watt JP, Hopewell PC, Flood J. Tuberculosis and HIV Co-infection, California, USA, 1993-2008. Emerg Infect Dis. 2012 Mar; 19(3):400-6.
        View in: PubMed
      14. Geng EH, Glidden DV, Bangsberg DR, Bwana MB, Musinguzi N, Nash D, Metcalfe JZ, Yiannoutsos CT, Martin JN, Petersen ML. A causal framework for understanding the effect of losses to follow-up on epidemiologic analyses in clinic-based cohorts: the case of HIV-infected patients on antiretroviral therapy in Africa. Am J Epidemiol. 2012 May 15; 175(10):1080-7.
        View in: PubMed
      15. Metcalfe JZ, Everett CK, Steingart KR, Cattamanchi A, Huang L, Hopewell PC, Pai M. Interferon-? release assays for active pulmonary tuberculosis diagnosis in adults in low- and middle-income countries: systematic review and meta-analysis. J Infect Dis. 2011 Nov 15; 204 Suppl 4:S1120-9.
        View in: PubMed
      16. Brust JC, O'Donnell MR, Metcalfe JZ. TB/HIV: an orphan disease? Am J Respir Crit Care Med. 2011 Jun 1; 183(11):1441-2.
        View in: PubMed
      17. Cattamanchi A, Smith R, Steingart KR, Metcalfe JZ, Date A, Coleman C, Marston BJ, Huang L, Hopewell PC, Pai M. Interferon-gamma release assays for the diagnosis of latent tuberculosis infection in HIV-infected individuals: a systematic review and meta-analysis. J Acquir Immune Defic Syndr. 2011 Mar 1; 56(3):230-8.
        View in: PubMed
      18. Kato-Maeda M, Metcalfe JZ, Flores L. Genotyping of Mycobacterium tuberculosis: application in epidemiologic studies. Future Microbiol. 2011 Feb; 6(2):203-16.
        View in: PubMed
      19. Metcalfe JZ, Kim EY, Lin SY, Cattamanchi A, Oh P, Flood J, Hopewell PC, Kato-Maeda M. Determinants of multidrug-resistant tuberculosis clusters, California, USA, 2004-2007. Emerg Infect Dis. 2010 Sep; 16(9):1403-9.
        View in: PubMed
      20. Davis JL, Worodria W, Kisembo H, Metcalfe JZ, Cattamanchi A, Kawooya M, Kyeyune R, den Boon S, Powell K, Okello R, Yoo S, Huang L. Clinical and radiographic factors do not accurately diagnose smear-negative tuberculosis in HIV-infected inpatients in Uganda: a cross-sectional study. PLoS One. 2010; 5(3):e9859.
        View in: PubMed
      21. Metcalfe JZ, Cattamanchi A, Vittinghoff E, Ho C, Grinsdale J, Hopewell PC, Kawamura LM, Nahid P. Evaluation of quantitative IFN-gamma response for risk stratification of active tuberculosis suspects. Am J Respir Crit Care Med. 2010 Jan 1; 181(1):87-93.
        View in: PubMed
      22. Cattamanchi A, Dantes RB, Metcalfe JZ, Jarlsberg LG, Grinsdale J, Kawamura LM, Osmond D, Hopewell PC, Nahid P. Clinical characteristics and treatment outcomes of patients with isoniazid-monoresistant tuberculosis. Clin Infect Dis. 2009 Jan 15; 48(2):179-85.
        View in: PubMed
      23. Gouveia EL, Metcalfe J, de Carvalho AL, Aires TS, Villasboas-Bisneto JC, Queirroz A, Santos AC, Salgado K, Reis MG, Ko AI. Leptospirosis-associated severe pulmonary hemorrhagic syndrome, Salvador, Brazil. Emerg Infect Dis. 2008 Mar; 14(3):505-8.
        View in: PubMed
      24. Roshanravan B, Kari E, Gilman RH, Cabrera L, Lee E, Metcalfe J, Calderon M, Lescano AG, Montenegro SH, Calampa C, Vinetz JM. Endemic malaria in the Peruvian Amazon region of Iquitos. Am J Trop Med Hyg. 2003 Jul; 69(1):45-52.
        View in: PubMed
      John's Networks
      Related Concepts
      Derived automatically from this person's publications.
      _
      Co-Authors
      People in Profiles who have published with this person.
      _
      Related Authors
      People who share related concepts with this person.
      _
      Back to TOP